Stephen Dahms, Biotechnology: What It Is, What It Is Not, and the Challenges in Reaching a National or Global Consensus, Biochemistry and Molecular Biology Education, Vol. 32, No. 4, pp. 271–278, 2004.
Fari MG, Kralovanszky UP. The founding father of biotechnology: Karoly (Karl) Ereky. International Journal of Horticultural Science 2006;12(1):9-12.
Bud R. Biotechnology in the twentieth century. Soc. Stud. Sci 1991;21(3):415-457.
Bull AT, Holt G, Lilly MD. Biotechnology: International Trends and Perspectives. Paris: Organisation for Economic Co-Operation and Development 1982
Verma AS, Agrahari S, Rastogi S, Singh A. Biotechnology in the realm of history. J Pharm Bioallied Sci 2011; 3(3): 321-323.
Kafarski P. Rainbow code of biotechnology. Chemik 2012; 66(8):811-816.
Demir-Dora D. Biyofarmasötik Ürünlerin Geliştirilmesinde Biyobelirteçler. Turkiye Klinikleri J Pharmacol- Special Topics 2017; 5(2):75-83.
Janvier S, Spiegeleer BD, Vanhee C, Deconinck E. Falsification of biotechnology drugs: current dangers and/or future disasters? Journal of Pharmaceutical and Biomedical Analysis 2018; 161: 175–191.
Sekhon BS. Biopharmaceuticals: an overview, Thai J. Pharm. Sci 2010; 34:1-19.
Ebbers HC, Tienda NF, Hoefnagel MC, Nibbeling R, Mantel-Teeuwisse AK. Characteristics of product recalls of biopharmaceuticals and small-molecule drugs in the USA. Drug Discov Today 2016; 21(4):536-539.
Declerck PJ. Biologicals and biosimilars: a review of the science and its implications. Generics and Biosimilars Initiative Journal (GaBI J) 2012; 1(1):13-6.
Castilho LR. Biopharmaceutical Products: An Introduction. Current Developments in Biotechnology and Bioengineering. Human and Animal Health Applications; 2017; p.3-21.
Part I of Annex I of Directive 2001/83/EC (as amended by Directive 2003/63/EC), https://ec.europa.eu/health/ sites/health/files/files/eudralex/ vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf (Erişim: 15.12.2019)
T.C. Sağlık Bakanlığı Türkiye Ilaç ve Tıbbi Cihaz Kurumu, Biyobenzer Ilaçlar Hakkında Kılavuz Taslağı. 30.05.2017, https://www.titck.gov.tr/ mevzuat/biyobenzer-tibbi-urunler-hakkinda-kilavuzu- taslagi-27122018173016 (Erişim: 15.12.2019)
ICH Harmonised Tripartite Guideline, Specifications: Test Pocedures and Acceptance Criteria for Biotechnological/Biological Products Q6B, 10.03.1999.
Walsh G. Protein Structure, In: Gary Walsh (Ed) Pharmaceutical Biotechnology Concepts and Applications. John Wiley and Sons Ltd, England, 2007; p 13-36.
Walsh G. Post-translational modification of protein pharmaceuticals. Drug Discov Today 2010; 15(17-18):773- 780.
Yalçın A. Posttranslasyonel modifikasyon ve protein fonksiyonu. Uludag Univ. J. Fac. Vet. Med 2012; 31:29-37.
Audagnotto M, Peraro MD. Protein post-translational modifications: In silico prediction tools and molecular Modeling. Comput. Struct. Biotechnol. J 2017; doi: 10.1016/j.csbj.2017.03.004.
Walsh G, Jefferies R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24:1241–1252.
Sandhu SS. Recombinant DNA Technology, IK International Publishing House Pvt Ltd New Delhi; 2010.
Griffiths E. Polypeptide production by recombinant DNA technology. In. Hider RC, Barlow D, eds. Polypeptide and Protein Drugs: Production, Characterization and Formulation, Ellis Horwood Limited, England; 1991; p.82-102.
Andersen DC, Krummen L. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 2002; 13:117-23.
Del Solar G, Espinosa M. Plasmid copy number control: an ever-growing story. Mol Microbiol 2000; 37:492-500.
Sorensen HP, Mortensen KK. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 2005; 115:113-28.
Carson M, Johnson DH, Mcdonald H, Brouillette C, Delucas LJ. His-tag impact on structure. Acta Crystallogr D Biol Crystallogr 2007; 63:295-301.
Demir D, Öner F, Rekombinant DNA Teknolojisi ile Bacillus Peptit Feromonunun Üretimi ve Transformasyon Etkinliğinin Optimizasyonu, Hacettepe Üniversitesi Sağlık Bilimleri Enstitüsü Farmasötik Biyoteknoloji Programı Doktora Tezi, Ankara, 2004.
Adrio JL, Demain AL. Recombinant organisms for production of industrial products. Bioeng Bugs 2010; 1:116-31.
Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 2009; 27:297–306.
Jonasson P., Liljeqvist S., Nygren P., Stahl S., Genetic design for facilated production and recovery of recombinant proteins in Escherichia coli, Biotechnol. Appl.
Biochem., 2002; 35:91-105.
Davis GD, Elisee C, Newham DM, Harrison RG. New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol Bioeng 1999; 65:382–388.
Meng YG, Liang J, Wong WL, Chisholm V. Green fluorescent protein as a second selectable marker for selection of high producing clones from transfected CHO cells. Gene 2000; 242:201–207.
Chen R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv 2012; 30(5):1102-7.
Chu L, Robinson DK. Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 2001; 12:180-7.
Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22:1393-8.
Sorensen HP, Mortensen KK, Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 2005; 115:113–128.
Winder R. Biomanufacturing, Cell culture changes gear. Chem Ind 2005; 20:18–20.
Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 2005; 68:283–291.
Giddings G, Allison G, Brooks D, Carter A. Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol 2000; 18:1151-1155.
Larrick JW, Thomas DW. Producing proteins in transgenic plant and animals. Curr Opin Biotechnol 2001; 12:411- 418.
European Medicines Agency (EMA). ICH Topic Q5D: Quality of Biotechnological Products: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products (CPMP/ ICH/294/95). 1998.
T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu, Beşeri ve İlaçlar İmalathaneleri İyi İmalat Uygulamaları (GMP) Kılavuzu, 05.05.2016.
European Pharmacopoeia 8.0, 5.14. Gene transfer medicinal products for human use, 705-716.
Ginai M, Elsby R, Hewitt CJ, Surry D, Fenner K, Coopman K. The use of biorecators as in vitro models in pharmaceutical research. Drug Discov Today 2013; 18(19-20):922-35.
Stanbury PF, Whitaker A, Hall SJ. Principles of Fermentation Technology Fermentation Technology, 2nd ed., Butterworth-Heinemann, Elsevier Science Oxford, 2003.
Kontoravdi C, Samsatli NJ, Shah N. Development and design of bio-pharmaceutical processes. Curr Opin Chem Eng 2013; 2:435–441.
Gronemeyer P, Ditz R and Strube J. Trends in Upstream and Downstream Process Development for Antibody Manufacturing, Bioengineering 2014; 1(4), 188- 212.
Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol 2009; 27:26-34.
Rathore AS. Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 2009; 27:546–553.
Lopes AG, Single-use in the biopharmaceutical industry: A review of current technology impact, challenges and limitations, food and bioproducts processing 2015; 93:98–114.
European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (EMA/CHMP/BWP/247713/2012 Rev1), 22 May 2014.
Hanke AT, Ottens M. Purifying biopharmaceuticals: knowledge-based chromatographic process development. Trends Biotechnol 2014; 32(4):210-220.
Cramer SM, Holstein MA. Downstream bioprocessing: recent advances and future promise. Curr Opin Chem Eng 2011; 1:27–37.
Samir Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev. Drug Discov 2004; 13:655–672.
Jameel F, Hershenson S.(Eds), Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, Wiley and Sons Inc., Hoboken, New Jersey, 2010.
Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res 2010; 27(4):544-75.
Tamizi E, Jouyban A, Forced degradation studies of biopharmaceuticals: selection of stres conditions, Eur J Pharm Biopharm 2016; 98: 26–46.
Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997; 17:15-21.
Ryff JC. Clinical investigation of immunogenicity of interferon-alpha 21. J Interferon Cytokine Res 1997; 17:29- 33.
Guidelines on packaging for pharmaceutical products, Annex 9. WHO Technical Report Series, No. 902, 2002.
Sharma B. Immunogenicity of therapeutic proteins. Part 2: impact of container closures. Biotechnol Adv 2007; 25:318-24.
Boven K, Stryker S, Knight J, Thomas A, Van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N. The increased incidence of pure red cell aplasia with an Eprex formulaton in uncoated rubber stopper syringes. Kidney Int 2005; 67:2346-53.
Casadevall N, Nataf J, Viron B, Kolta A, Kılanjıan JJ et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346(7):469-475.
ICH Harmonised Tripartite Guideline, Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, Q5C.
Wang W, Singh SK., Li N, Toler ML, King KR, Nema S. Immunogenicity of protein aggregates-concern and realities. Int J Pharm 2012; 431:1-11.
Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biotherapeuticals. Nephrol Dial Transplant 2006; 21: 9-12.
Barbosa M. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov Today 2011; 16:7-8.
Committee for Medicinal Products for Human Use (CHMP), Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (EMEA/CHMP/BMWP/14327/2006), 13 December 2007.
Korucu FC, Nazlı H, Gedik G, Çiçin I. Biyobenzer ürünlerde klinik uygulamada karşılaşılabilecek sorunlar. Marmara Pharm J 2016; 20:44-51.
Parkins DA, Lashmar UT. The formulation of biopharmaceutical products. Pharm Sci Technol Today 2000; 3(4):129–37.